Literature DB >> 26059502

Prevalence and Perioperative Outcomes of Off-Label Total Hip and Knee Arthroplasty in the United States, 2000-2010.

Tennison Malcolm1, Caleb R Szubski2, Nicholas K Schiltz3, Alison K Klika2, Siran M Koroukian3, Wael K Barsoum2.   

Abstract

"Off-label use" refers to medical device utilization for purposes or subpopulations other than those approved by the United States Food and Drug Administration. The primary goal of this study was to determine the current epidemiology of off-label total hip and knee arthroplasties (THA and TKA, respectively) in the United States and to project further off-label use through 2040. Over the past decade, the prevalence of off-label THA and TKA was 30.4% and 37.0%, respectively, growing ~70% from 2000 to 2010. By 2040, the majority of THAs (86.1%) and TKAs (91.5%) could be off-label. The high prevalence of off-label arthroplasty and the dramatically shifting patient profile illustrated by these results highlight the need for continued medical device surveillance among on- and off label patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  complications; off-label; prevalence; projections; total hip arthroplasty; total knee arthroplasty

Mesh:

Year:  2015        PMID: 26059502      PMCID: PMC4640948          DOI: 10.1016/j.arth.2015.05.020

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  29 in total

1.  Trends in demographics, comorbidity profiles, in-hospital complications and mortality associated with primary knee arthroplasty.

Authors:  Stavros G Memtsoudis; Alejandro González Della Valle; Melanie C Besculides; Licia Gaber; Richard Laskin
Journal:  J Arthroplasty       Date:  2008-04-15       Impact factor: 4.757

2.  Industry-sponsored clinical research: a broken system.

Authors:  Marcia Angell
Journal:  JAMA       Date:  2008-09-03       Impact factor: 56.272

3.  Off-label use of bone morphogenetic proteins in the United States using administrative data.

Authors:  Kevin L Ong; Marta L Villarraga; Edmund Lau; Leah Y Carreon; Steven M Kurtz; Steven D Glassman
Journal:  Spine (Phila Pa 1976)       Date:  2010-09-01       Impact factor: 3.468

4.  Gastric bypass as treatment for obesity: trends, characteristics, and complications.

Authors:  Judith A Shinogle; Maria F Owings; Lola Jean Kozak
Journal:  Obes Res       Date:  2005-12

5.  Acute delirium and poor compliance in total hip arthroplasty patients with substance abuse disorders.

Authors:  Yi-Hsun Yu; Alvin C-Y Chen; Chih-Chien Hu; Pang-Hsin Hsieh; Steve W N Ueng; Mel S Lee
Journal:  J Arthroplasty       Date:  2012-02-08       Impact factor: 4.757

6.  The obesity epidemic: its effect on total joint arthroplasty.

Authors:  Thomas K Fehring; Susan M Odum; William L Griffin; J Bohannon Mason; Thomas H McCoy
Journal:  J Arthroplasty       Date:  2007-07-26       Impact factor: 4.757

7.  The impact of glycemic control and diabetes mellitus on perioperative outcomes after total joint arthroplasty.

Authors:  Milford H Marchant; Nicholas A Viens; Chad Cook; Thomas Parker Vail; Michael P Bolognesi
Journal:  J Bone Joint Surg Am       Date:  2009-07       Impact factor: 5.284

8.  Total HIP arthroplasty in patients with Parkinson's disease.

Authors:  Pradeep George Mathew; Pavel Sponer; Tomás Kucera; Michal Grinac; Jirí Knízek
Journal:  Acta Medica (Hradec Kralove)       Date:  2013

9.  Hip arthroplasty in mentally impaired patients.

Authors:  M D Ries; D Wolff; J A Shaul
Journal:  Clin Orthop Relat Res       Date:  1994-11       Impact factor: 4.176

10.  Joint Arthroplasties other than the Hip in Solid Organ Transplant Recipients.

Authors:  Arkan S Sayed-Noor
Journal:  Open Orthop J       Date:  2009-05-15
View more
  6 in total

1.  Nationwide review of mixed and non-mixed components from different manufacturers in total hip arthroplasty.

Authors: 
Journal:  Acta Orthop       Date:  2016-09-23       Impact factor: 3.717

2.  Patients With Multiple Myeloma Have More Complications After Surgical Treatment of Hip Fracture.

Authors:  Kwan Jun Park; Mariano E Menendez; Simon C Mears; C Lowry Barnes
Journal:  Geriatr Orthop Surg Rehabil       Date:  2016-07-14

Review 3.  EFORT recommendations for off-label use, mix & match and mismatch in hip and knee arthroplasty.

Authors:  Keith Tucker; Klaus-Peter Günther; Per Kjaersgaard-Andersen; Jörg Lützner; Jan Philippe Kretzer; Rob G H H Nelissen; Toni Lange; Luigi Zagra
Journal:  EFORT Open Rev       Date:  2021-11-19

4.  Nationwide review of mixed and non-mixed components from different manufacturers in total hip arthroplasty.

Authors:  Rinne M Peters; Liza N van Steenbergen; Sjoerd K Bulstra; Adelgunde V C M Zeegers; Roy E Stewart; Rudolf W Poolman; Anton H Hosman
Journal:  Acta Orthop       Date:  2016-06-27       Impact factor: 3.717

5.  The efficacy and safety of multiple versus single doses dexamethasone in unicompartmental knee arthroplasty: A protocol of randomized controlled trial.

Authors:  Dehong Gao; Xin Liu; Fan Zhang; Mingyan Ding
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.889

6.  Femoral nerve block versus obturator nerve block for pain management after total knee replacement: A randomized controlled trial protocol.

Authors:  Wei Zhang; Peng Lin; Fuheng Zhang; Ji Wang
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.